LumiraDx Sells Point of Care Technology Platform to Roche for up to $350 Million

UK-based LumiraDx has signed a definitive agreement to sell certain of its point-of-care technology businesses to Roche, which will pay a purchase price of USD 295 million plus an additional payment of up to USD 55 million for the reimbursement of amounts used to fund the point-of-care diagnostics platform business until the acquisition is completed.

The completion of the transaction is subject to certain conditions, including antitrust and regulatory approvals, and is currently expected to close by mid-2024.

We are delighted to enter into this agreement with Roche as it will allow us to continue our important work and expand the reach of our innovative technology around the world, enabling more patients to have quick and easy access to better diagnostic tests,” said Veronique Ameye, CEO of LumiraDx.

To view the source version, please click HERE.

en_GBEnglish (UK)